California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The K-Map Study, Global Prevalence of KC
NCT03115710
Recruiting
Keratoconus is a ocular disease classified under ectatic diseases which often results in bilateral and asymmetrical corneal distortion. It usually affects patients at young age and can cause severe visual loss. The overall goal of this study is to assess the prevalence of keratoconus (KC) in children and adolescents in various regions of the world based on modern tomographic imaging methods, and to verify whether the occurrence rates reported from literature should be corrected. Our hypothesis... Read More
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
08/06/2025
Locations: USC Roski Eye Institute, Los Angeles, California
Conditions: Keratoconus
Register for Updates
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
NCT02704858
Recruiting
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase 1 is a standard cohort dose escalation 3+3 design used to determine the maximum tolerated dose for Phase 2a. There will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: University of Southern California, Los Angeles, California
Conditions: Glioblastoma Multiforme
Register for Updates
Pompe Disease Registry Protocol
NCT00231400
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: * To enhance understanding of t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/06/2025
Locations: University of California at Irvine- Site Number : 840036, Irvine, California
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Register for Updates
Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke
NCT07118189
Recruiting
The overarching goal of this project is to conduct a pilot intervention in high-risk Kaiser Permanente Northern California patients with chronic obstructive pulmonary disease to mitigate their exposure to poor air quality and decrease exacerbations of lung disease.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/05/2025
Locations: Kaiser Permanente Northern California Division of Research, Pleasanton, California
Conditions: Chronic Obstructive Pulmonary Disease (COPD), Exacerbation of COPD, Exacerbation of Chronic Obstructive Pulmonary Disease
Register for Updates
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
NCT07118176
Recruiting
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Bec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Lung Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Neoplasm of Unknown Primary, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Uterine Neoplasm, Neuroendocrine Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Penile Carcinoma, Pleural Carcinomatosis, Primary Peritoneal Carcinoma, Prostate Carcinoma, Salivary Gland Carcinoma, Sarcoma, Skin Carcinoma, Solitary Fibrous Tumor, Thymus Carcinoma, Thyroid Gland Carcinoma, Thyroid Gland Medullary Carcinoma, Urothelial Carcinoma, Vaginal Carcinoma
Register for Updates
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
NCT07086677
Recruiting
The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: * an experimental PG4 vaccine * a PG4 vaccine comparator * a standard 20vPnC vaccine comparator * placebo. A placebo does not have any medicine in it but looks just like the study medicine. Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to t... Read More
Gender:
ALL
Ages:
Between 65 years and 84 years
Trial Updated:
08/05/2025
Locations: Orange County Research Center, Lake Forest, California
Conditions: Streptococcus Pneumoniae
Register for Updates
Impact of a Novel Brain Longevity Supplement Containing the Postbiotic Urolithin A (Mitopure) on Cognitive Function and Related Health Outcomes
NCT07060898
Recruiting
This is a parallel group, randomized, double-blind, placebo-controlled clinical study assessing the safety and effects of a novel nutritional product on self-reported cognitive function and health in adults that reside in the USA. Participants will take their assigned study product (active or placebo) for 8 weeks and answer validated electronic surveys assessing cognitive function delivered to them through a text message (SMS) link or through email.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/05/2025
Locations: Radicle Science, Inc Office, Encinitas, California
Conditions: Aging, Cognitive Decline, Brain Fog, Cognitive Function
Register for Updates
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
NCT06975722
Recruiting
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: Gastro Care Institute - Site Number: 8400006, Lancaster, California
Conditions: Ulcerative Colitis
Register for Updates
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805
Recruiting
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/05/2025
Locations: WISPer site in Newport Beach, CA, Newport Beach, California
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536
Recruiting
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: Gastro Care Institute - Site Number: 8400001, Lancaster, California
Conditions: Crohn's Disease
Register for Updates
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
NCT06914609
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Gender:
ALL
Ages:
Between 2 years and 50 years
Trial Updated:
08/05/2025
Locations: Rady Children's Hospital, San Diego, California
Conditions: Angelman Syndrome
Register for Updates
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
NCT06906497
Recruiting
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Physioseq USA - CA, Folsom, California
Conditions: Atopic Dermatitis
Register for Updates